Tags

Type your tag names separated by a space and hit enter

The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients.
Transpl Int. 2012 Feb; 25(2):166-71.TI

Abstract

Limited data are available regarding antibody response and the safety of the monovalent influenza A H1N1/09 vaccine for immunocompromised patients. In this study, the humoral response to this vaccine in solid organ transplant (SOT) recipients and healthy individuals was evaluated. Eighty-two SOT recipients and 28 healthy individuals received two doses of the influenza A H1N1/09 AS03 adjuvanted vaccine containing 3.75 mg of haemagglutinin at a 3- to 4-week interval. Serum samples were drawn at baseline and 3-4 weeks after the first and second vaccine doses. Seroprotective titres were measured with a haemagglutination inhibition. After the first dose seroprotective titres were observed in 69% of the SOT patients and in 96% of the healthy controls (P = 0.006), and increased after the second dose to 80% and 100%, respectively (P = 0.003). All controls and 77% of the SOT recipients achieved a ≥4-fold titre rise after the first immunisation (P = 0.005). The vaccine was well tolerated and no acute rejection was observed. Influenza A H1N1/09 vaccine elicited a protective antibody response in the majority of SOT recipients, but the response was lower when compared with controls. A second dose significantly improved vaccine immunogenicity in SOT recipients. (ClinicalTrials.gov number: NCT01254955).

Authors+Show Affiliations

Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden. marie.felldin@surgery.gu.seNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22117586

Citation

Felldin, Marie, et al. "The Antibody Response to Pandemic H1N1 2009 Influenza Vaccine in Adult Organ Transplant Patients." Transplant International : Official Journal of the European Society for Organ Transplantation, vol. 25, no. 2, 2012, pp. 166-71.
Felldin M, Studahl M, Svennerholm B, et al. The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. Transpl Int. 2012;25(2):166-71.
Felldin, M., Studahl, M., Svennerholm, B., & Friman, V. (2012). The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. Transplant International : Official Journal of the European Society for Organ Transplantation, 25(2), 166-71. https://doi.org/10.1111/j.1432-2277.2011.01391.x
Felldin M, et al. The Antibody Response to Pandemic H1N1 2009 Influenza Vaccine in Adult Organ Transplant Patients. Transpl Int. 2012;25(2):166-71. PubMed PMID: 22117586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. AU - Felldin,Marie, AU - Studahl,Marie, AU - Svennerholm,Bo, AU - Friman,Vanda, Y1 - 2011/11/26/ PY - 2011/11/29/entrez PY - 2011/11/29/pubmed PY - 2012/5/15/medline SP - 166 EP - 71 JF - Transplant international : official journal of the European Society for Organ Transplantation JO - Transpl Int VL - 25 IS - 2 N2 - Limited data are available regarding antibody response and the safety of the monovalent influenza A H1N1/09 vaccine for immunocompromised patients. In this study, the humoral response to this vaccine in solid organ transplant (SOT) recipients and healthy individuals was evaluated. Eighty-two SOT recipients and 28 healthy individuals received two doses of the influenza A H1N1/09 AS03 adjuvanted vaccine containing 3.75 mg of haemagglutinin at a 3- to 4-week interval. Serum samples were drawn at baseline and 3-4 weeks after the first and second vaccine doses. Seroprotective titres were measured with a haemagglutination inhibition. After the first dose seroprotective titres were observed in 69% of the SOT patients and in 96% of the healthy controls (P = 0.006), and increased after the second dose to 80% and 100%, respectively (P = 0.003). All controls and 77% of the SOT recipients achieved a ≥4-fold titre rise after the first immunisation (P = 0.005). The vaccine was well tolerated and no acute rejection was observed. Influenza A H1N1/09 vaccine elicited a protective antibody response in the majority of SOT recipients, but the response was lower when compared with controls. A second dose significantly improved vaccine immunogenicity in SOT recipients. (ClinicalTrials.gov number: NCT01254955). SN - 1432-2277 UR - https://www.unboundmedicine.com/medline/citation/22117586/The_antibody_response_to_pandemic_H1N1_2009_influenza_vaccine_in_adult_organ_transplant_patients_ L2 - https://doi.org/10.1111/j.1432-2277.2011.01391.x DB - PRIME DP - Unbound Medicine ER -